Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KB707 |
Synonyms | |
Therapy Description |
KB707 is a vector derived from a replication-defective herpes simplex virus type 1 (HSV-1) and engineered to express IL-12 and IL-2, which potentially results in antitumor activity (Journal for ImmunoTherapy of Cancer 2023;11). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KB707 | KB-707|KB 707 | KB707 is a vector derived from a replication-defective herpes simplex virus type 1 (HSV-1) and engineered to express IL-12 and IL-2, which potentially results in antitumor activity (Journal for ImmunoTherapy of Cancer 2023;11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05970497 | Phase I | KB707 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06228326 | Phase I | KB707 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Recruiting | USA | 0 |